Cargando…

Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production

BACKGROUND & AIMS: Cyclophilins are host factors required for hepatitis C virus replication. Cyclophilin inhibitors such as alisporivir have shown strong anti–hepatitis C virus activity in vitro and in clinical studies. However, little is known about whether hepatocyte cyclophilins are involved...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Sandra, Chokshi, Shilpa, Chatterji, Udayan, Riva, Antonio, Bobardt, Michael, Williams, Roger, Gallay, Philippe, Naoumov, Nikolai V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AGA Institute. Published by Elsevier Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172380/
https://www.ncbi.nlm.nih.gov/pubmed/25305505
http://dx.doi.org/10.1053/j.gastro.2014.10.004
_version_ 1783524246593470464
author Phillips, Sandra
Chokshi, Shilpa
Chatterji, Udayan
Riva, Antonio
Bobardt, Michael
Williams, Roger
Gallay, Philippe
Naoumov, Nikolai V.
author_facet Phillips, Sandra
Chokshi, Shilpa
Chatterji, Udayan
Riva, Antonio
Bobardt, Michael
Williams, Roger
Gallay, Philippe
Naoumov, Nikolai V.
author_sort Phillips, Sandra
collection PubMed
description BACKGROUND & AIMS: Cyclophilins are host factors required for hepatitis C virus replication. Cyclophilin inhibitors such as alisporivir have shown strong anti–hepatitis C virus activity in vitro and in clinical studies. However, little is known about whether hepatocyte cyclophilins are involved in the hepatitis B virus (HBV) life cycle. We investigated the effects of 2 cyclophilin inhibitors (alisporivir and NIM811) on HBV replication and hepatitis B surface antigen (HBsAg) production in cell lines. METHODS: Liver-derived cell lines producing full-length HBV and HBsAg particles, owing to stable (HepG2215) or transient (HuH-7) transfection, or infected with HBV (HepaRG cells; Invitrogen [Carlsbad, CA]), were incubated with alisporivir or NIM811 alone, or alisporivir in combination with a direct antiviral (telbivudine). The roles of individual cyclophilins in drug response was evaluated by small interfering RNA knockdown of cyclophilin (CYP)A, CYPC, or CYPD in HepG2215 cells, or CYPA knockdown in HuH-7 cells. The kinetics of antiviral activity were assessed based on levels of HBV DNA and HBsAg and Southern blot analysis. RESULTS: In HepG2215, HuH-7, and HepaRG cells, alisporivir reduced intracellular and secreted HBV DNA, in a dose-dependent manner. Knockdown of CYPA, CYPC, or CYPD (reduced by 80%) significantly reduced levels of HBV DNA and secreted HBsAg. Knockdown of CYPA significantly reduced secretion of HBsAg, leading to accumulation of intracellular HBsAg; the addition of alisporivir greatly reduced levels of HBsAg in these cells. The combination of alisporivir and telbivudine had greater antiviral effects than those of telbivudine or alisporivir alone. CONCLUSIONS: Alisporivir inhibition of cyclophilins in hepatocyte cell lines reduces replication of HBV DNA and HBsAg production and secretion. These effects are potentiated in combination with direct antiviral agents that target HBV-DNA polymerase.
format Online
Article
Text
id pubmed-7172380
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher AGA Institute. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71723802020-04-22 Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production Phillips, Sandra Chokshi, Shilpa Chatterji, Udayan Riva, Antonio Bobardt, Michael Williams, Roger Gallay, Philippe Naoumov, Nikolai V. Gastroenterology Original Research BACKGROUND & AIMS: Cyclophilins are host factors required for hepatitis C virus replication. Cyclophilin inhibitors such as alisporivir have shown strong anti–hepatitis C virus activity in vitro and in clinical studies. However, little is known about whether hepatocyte cyclophilins are involved in the hepatitis B virus (HBV) life cycle. We investigated the effects of 2 cyclophilin inhibitors (alisporivir and NIM811) on HBV replication and hepatitis B surface antigen (HBsAg) production in cell lines. METHODS: Liver-derived cell lines producing full-length HBV and HBsAg particles, owing to stable (HepG2215) or transient (HuH-7) transfection, or infected with HBV (HepaRG cells; Invitrogen [Carlsbad, CA]), were incubated with alisporivir or NIM811 alone, or alisporivir in combination with a direct antiviral (telbivudine). The roles of individual cyclophilins in drug response was evaluated by small interfering RNA knockdown of cyclophilin (CYP)A, CYPC, or CYPD in HepG2215 cells, or CYPA knockdown in HuH-7 cells. The kinetics of antiviral activity were assessed based on levels of HBV DNA and HBsAg and Southern blot analysis. RESULTS: In HepG2215, HuH-7, and HepaRG cells, alisporivir reduced intracellular and secreted HBV DNA, in a dose-dependent manner. Knockdown of CYPA, CYPC, or CYPD (reduced by 80%) significantly reduced levels of HBV DNA and secreted HBsAg. Knockdown of CYPA significantly reduced secretion of HBsAg, leading to accumulation of intracellular HBsAg; the addition of alisporivir greatly reduced levels of HBsAg in these cells. The combination of alisporivir and telbivudine had greater antiviral effects than those of telbivudine or alisporivir alone. CONCLUSIONS: Alisporivir inhibition of cyclophilins in hepatocyte cell lines reduces replication of HBV DNA and HBsAg production and secretion. These effects are potentiated in combination with direct antiviral agents that target HBV-DNA polymerase. AGA Institute. Published by Elsevier Inc. 2015-02 2014-10-08 /pmc/articles/PMC7172380/ /pubmed/25305505 http://dx.doi.org/10.1053/j.gastro.2014.10.004 Text en Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Research
Phillips, Sandra
Chokshi, Shilpa
Chatterji, Udayan
Riva, Antonio
Bobardt, Michael
Williams, Roger
Gallay, Philippe
Naoumov, Nikolai V.
Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
title Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
title_full Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
title_fullStr Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
title_full_unstemmed Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
title_short Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
title_sort alisporivir inhibition of hepatocyte cyclophilins reduces hbv replication and hepatitis b surface antigen production
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172380/
https://www.ncbi.nlm.nih.gov/pubmed/25305505
http://dx.doi.org/10.1053/j.gastro.2014.10.004
work_keys_str_mv AT phillipssandra alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction
AT chokshishilpa alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction
AT chatterjiudayan alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction
AT rivaantonio alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction
AT bobardtmichael alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction
AT williamsroger alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction
AT gallayphilippe alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction
AT naoumovnikolaiv alisporivirinhibitionofhepatocytecyclophilinsreduceshbvreplicationandhepatitisbsurfaceantigenproduction